CNS and GI - Page 1

Pfizer Lyrica drug fails to meet primary endpoint
Tuesday, May 08, 2012 Pfizer's Lyrica (pregabalin) drug has failed to meet its primary efficacy endpoint in a Phase 3 randomised study of patients with inadequately treated painful diabetic peripheral neuropathy...

Gammagard Liquid 10% meets primary efficacy endpoints in Phase III study
Monday, April 30, 2012 Baxter International has announced Phase III clinical data investigating the safety and efficacy of Gammagard Liquid 10%, intended for the treatment of multifocal motor neuropathy...

Levomilnacipran reports positive data in Phase III study
Friday, April 27, 2012 Forest Laboratories and Pierre Fabre Medicament have announced additional positive results from a Phase III clinical trial of Levomilnacipran (1S, 2R-milnacipran), an investigational agent for...

Biogen Idec multiple sclerosis drug reports positive Phase 3 data
Wednesday, April 25, 2012 Biogen Idec's oral BG-12 (dimethyl fumarate) drug demonstrated safety and efficacy data in the second Phase 3 Comparator and an Oral Fumarate in RRMS (CONFIRM)...

Sanofi, MJFF form alliance to evaluate Parkinson's drug
Friday, April 20, 2012 Sanofi has entered into a partnership with the Michael J. Fox Foundation (MJFF) to investigate the safety and tolerability of AVE 8112, a Sanofi phosphodiesterase type 4 (PDE4) inhibitor...

Cubist Entereg drug meets Phase 4 study endpoints
Thursday, April 19, 2012 Cubist Pharmaceuticals' Entereg (alvimopan) has met the primary endpoint of time to achieve recovery of both upper and lower gastrointestinal (GI) function and secondary endpoints, including...

Levodopa-carbidopa intestinal gel shows efficacy against Parkinson's: Abbott reports
Wednesday, April 18, 2012 Abbott has reported the results from the Phase 3 trial evaluating its investigational compound levodopa-carbidopa intestinal gel (LCIG), used for the treatment of advanced Parkinson's disease...

ProSavin meets endpoints in Parkinson's study
Tuesday, April 17, 2012 Oxford BioMedica, a gene-based biopharmaceutical company, has concluded a Phase I/II study to evaluate the safety, efficacy and dose evaluation of ProSavin in patients with mid-stage...

Sinovac EV71 vaccine shows efficacy against hand, foot and mouth disease
Friday, March 30, 2012 Sinovac Biotech has announced the positive Phase I clinical data of its inactivated Enterovirus 71 (EV71) vaccine, indicated for the prevention of hand, foot and mouth disease...

NIAID funds Emergent BioSolutions to advance tuberculosis vaccine
Monday, March 26, 2012 Emergent BioSolutions has secured a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, to advance the development...

Dipraglurant drug meets endpoints: Addex reports
Friday, March 23, 2012 Addex Therapeutics has reported positive top line data from a Phase IIa clinical study of its dipraglurant drug in patients suffering from Parkinson's Disease Levodopa-Induced Dyskinesia...

TC-5214 Phase III studies fail to meet primary endpoint
Wednesday, March 21, 2012 AstraZeneca and Targacept have reported the data from the remaining Phase III studies evaluating the efficacy, tolerability and safety of TC-5214 as an adjunct therapy to an antidepressant...

Repligen begins Phase 1 study of RG2833
Monday, March 19, 2012 Repligen Corporation has enrolled the first patient with Friedreich's ataxia (FA) in its Phase 1 clinical trial of RG2833, an orally bioavailable, class 1 histone deacetylase inhibitor...

Cariprazine drug found effective in Phase III trials for schizophrenia
Wednesday, February 29, 2012 Gedeon Richter's Cariprazine (RGH-188) drug has demonstrated positive top-line results from the two Phase III clinical trials in patients with acute exacerbation of...

TxCell reports positive immuno-monitoring results from Crohn's disease study
Wednesday, February 22, 2012 TxCell, a biotechnology company, has reported positive immuno-monitoring results from Phase I/II study in Crohn's disease (CATS1) with...

Takeda Phase III ulcerative colitis trial meets primary endpoints
Tuesday, February 21, 2012 Takeda Pharmaceutical Company has announced positive top-line results from a pivotal Phase III trial of vedolizumab in patients with moderately to severely active ulcerative colitis, who...

Soligenix reports phase 1/2 trial data of SGX201
Monday, February 13, 2012 Soligenix, a development stage biopharmaceutical company, has reported the preliminary results from its Phase 1/2 clinical study of SGX201, a time-release formulation of oral...

Cariprazine monotherapy shows efficacy against bipolar I disorder
Thursday, February 09, 2012 Forest Laboratories and Gedeon Richter have reported preliminary top-line results from a Phase III clinical trial of Cariprazine (RGH-188), an investigational anti-psychotic agent, used to...

Avanir Pharmaceuticals reports Phase III data of AVP-923
Thursday, February 09, 2012 Avanir Pharmaceuticals has reported safety and efficacy results of its AVP-923 medication in the study entitled "Efficacy and Safety of Dextromethorphan/Quinidine (AVP-923) at Two Dosage Levels...

EpiCept files fast track status for AmiKet
Wednesday, February 08, 2012 EpiCept Corporation has filed a fast track designation with the US Food and Drug Administration (FDA) for its AmiKet, used for the treatment of chemotherapy-induced peripheral neuropathy...